Company intelligence
DELFI Diagnostics
DELFI's AI and whole-genome sequencing platform powers FirstLook Lung, a blood-based lung cancer screening test.
Medical and Diagnostic Laboratories
Palo Alto, US
151 employees
Founded 2019
4 public signals
About DELFI Diagnostics
DELFI uses AI, machine learning and whole genome sequencing to sensitively detect unique patterns of DNA fragmentation in the blood of patients with cancer.
Verified activity
Signals from DELFI Diagnostics
4 published signals
People
DELFI Diagnostics welcomed Kandasamy Ravi, PhD, as the new Vice President of Product Development.
Reported by DELFI Diagnostics
Presence & Recognition
DELFI Diagnostics launched a new home for AI and early cancer detection, including exhibiting at the Go2 for Lung Cancer COE Summit, the DC Lung Cancer Conference, and the Rescue Lung Society Conference, presenting at Data Driven Pharma West, ESMO, and West Healthcare Innovation Summit, and more stops through AACR and ATS in 2027.
Reported by DELFI Diagnostics
Products & Services
DELFI Diagnostics built a program called LungMATCH for patients to navigate lung cancer treatment, biomarker testing, and clinical trials.
Reported by DELFI Diagnostics
Research & Knowledge
DELFI Diagnostics published a study by researchers at Huazhong University of Science and Technology in China following 269,173 screening program participants for a median of 8.61 years, finding that people with a negative LDCT scan had long-term lung cancer incidence, mortality, and all-cause mortality similar to the low-risk group.
Reported by DELFI Diagnostics